Chronic Bronchitis Market: By Treatment (Pharmacological, Nonpharmacological, and Others), By Drug Class (Bronchodilators, Glucocorticoids, Antibiotics, Phosphodiesterase-4 Inhibitors, and Others), By Route of Administration (Oral, Parenteral, Inhalational, and Others), By End Users (Hospitals, Specialty Clinics, and Others) and Geography

Chronic Bronchitis Market was valued at USD 5.8 billion in 2022 and is poised to grow at a CAGR of 5.4% over 2023-2029. Chronic Bronchitis is defined as a productive cough, one that produces sputum, which lasts for three months or more per year for at least two years, and the most common cause is tobacco smoking, including other factors such as air pollution and genetics. According to the Centers for Disease Control and Prevention, 9.3 million people were diagnosed with chronic bronchitis in the USA, in 2018. The increasing prevalence of COPD and growing chronic bronchitis market demand for combination therapy will act as the chronic bronchitis market growth drivers. However, the high cost of treatment and the lack of awareness of the disease might cause hindrance in the growth of the market. The rising prevalence of smoking and advancements in clinical research and innovations are opportunities for the expansion of the market.

Chronic Bronchitis Market Key Developments:

• In Feb 2022, AstraZeneca and Glenmark Pharmaceuticals Ltd. entered into an exclusive licensing agreement for Budesonide inhalation suspension in Colombia.
• In Feb 2022, Sunovion’s Brovana was approved by the US FDA for treating bronchoconstriction in chronic obstructive pulmonary disease patients.